📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Development of a low-seroprevalence, avß6 integrin-selective virotherapy based on human adenovirus type 10. (2022)

First Author: Bates EA

Attributed to: MICA: Targeting the Wnt Receptor Frizzled-7 for the Treatment of Gastric Cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.omto.2022.03.007

PubMed Identifier: 35399606

Publication URI: http://europepmc.org/abstract/MED/35399606

Type: Journal Article/Review

Volume: 25

Parent Publication: Molecular therapy oncolytics

ISSN: 2372-7705